Education
About Us
Working with TipRanks
Follow Us
Madrigal Pharmaceuticals Inc (MDGL)
NASDAQ:MDGL
MDGL Stock Chart & Stats
$480.45
-$1.78(-0.55%)
At close: 4:00 PM EST
$480.45
-$1.78(-0.55%)
Day’s Range― - ―
52-Week Range$265.00 - $615.00
Previous CloseN/A
Volume47.78K
Average Volume (3M)296.72K
Market Cap
$10.91B
Enterprise Value$10.96B
Total Cash (Recent Filing)$1.11B
Total Debt (Recent Filing)$346.40M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Mar 04, 2026EPS Estimate
-0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.08
Shares Outstanding22,711,420
10 Day Avg. Volume277,062
30 Day Avg. Volume296,724
Financial Highlights & Ratios
PEG Ratio-1.47
Price to Book (P/B)8.70
Price to Sales (P/S)36.44
P/FCF Ratio-14.36
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue14.80
Enterprise Value/Gross Profit15.54
Enterprise Value/Ebitda-40.58
Forecast
1Y Price Target
$660.44Price Target Upside37.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Combination Therapy PotentialComplementary mechanisms between the DGAT-2 inhibitor and Rezdiffra support planned combination trials, which could produce additive clinical benefits and improved liver and lipid outcomes.
Commercial Traction And AccessBroad insurer coverage and expanding prescriber support for Rezdiffra, along with rising patient uptake, underpin a foundation for sustained commercial growth and positioning as an oral backbone therapy.
Strategic LicensingExclusive global license from Pfizer grants rights to develop, manufacture, and commercialize an oral DGAT-2 inhibitor and two early-stage MASH assets, strengthening Madrigal's pipeline and control over combination strategies.
Bears Say
Class Safety ConcernsEmerging safety signals in the DGAT inhibitor class could elevate perceived safety risks for ervogastat and complicate regulatory review and clinician adoption.
Competition And Access HeadwindsLow-cost GLP-1 competitors, more potent FGF21 entrants, prescriber skepticism about MASH, and administrative barriers like diagnostic access could constrain market penetration and pricing power.
Monotherapy Efficacy RiskHistorical DGAT-2 monotherapy data indicated limited efficacy, implying ervogastat may require combination use to achieve meaningful clinical benefit.
Madrigal Pharmaceuticals News
MDGL FAQ
What was Madrigal Pharmaceuticals Inc’s price range in the past 12 months?
Madrigal Pharmaceuticals Inc lowest stock price was $265.00 and its highest was $615.00 in the past 12 months.
What is Madrigal Pharmaceuticals Inc’s market cap?
Madrigal Pharmaceuticals Inc’s market cap is $10.91B.
When is Madrigal Pharmaceuticals Inc’s upcoming earnings report date?
Madrigal Pharmaceuticals Inc’s upcoming earnings report date is Mar 04, 2026 which is in 37 days.
How were Madrigal Pharmaceuticals Inc’s earnings last quarter?
Madrigal Pharmaceuticals Inc released its earnings results on Nov 04, 2025. The company reported -$5.08 earnings per share for the quarter, missing the consensus estimate of -$2.285 by -$2.795.
Is Madrigal Pharmaceuticals Inc overvalued?
According to Wall Street analysts Madrigal Pharmaceuticals Inc’s price is currently Undervalued.
Does Madrigal Pharmaceuticals Inc pay dividends?
Madrigal Pharmaceuticals Inc does not currently pay dividends.
What is Madrigal Pharmaceuticals Inc’s EPS estimate?
Madrigal Pharmaceuticals Inc’s EPS estimate is -0.92.
How many shares outstanding does Madrigal Pharmaceuticals Inc have?
Madrigal Pharmaceuticals Inc has 22,711,420 shares outstanding.
What happened to Madrigal Pharmaceuticals Inc’s price movement after its last earnings report?
Madrigal Pharmaceuticals Inc reported an EPS of -$5.08 in its last earnings report, missing expectations of -$2.285. Following the earnings report the stock price went up 7.831%.
Which hedge fund is a major shareholder of Madrigal Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in MDGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Madrigal Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$660.44 (37.46% Upside)
$660.44 (37.46% Upside)
Blogger Sentiment
Bullish
MDGL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 119.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $9.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 7.3%
Last 30 Days ▲ 7.3%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.25%
12-Months-Change
Fundamentals
Return on Equity
-41.22%
Trailing 12-Months
Asset Growth
26.95%
Trailing 12-Months
Company Description
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
MDGL Company Deck
MDGL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a strong quarter for Madrigal Pharmaceuticals, driven by the successful launch of Rezdiffra and robust financial health. However, increased operating expenses and ongoing challenges with payer contracting highlight areas of concern. Additionally, competitive pressures from other entrants in the MASH market could impact future growth. Overall, the sentiment is cautiously optimistic.View all MDGL earnings summariesMDGL Stock 12 Month Forecast
Average Price Target
$660.44
▲(37.46% Upside)
Technical Analysis
Exelixis
―
Ionis Pharmaceuticals
―
Ascendis Pharma
―
BridgeBio Pharma
―
Roivant Sciences
―
Ownership Overview
Currently, No data available
---